Vincent J Picozzi

Summary

Affiliation: Virginia Mason Medical Center
Country: USA

Publications

  1. ncbi request reprint Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma
    Vincent J Picozzi
    Department of General Surgery, Virginia Mason Medical Center, Seattle, WA 98111, USA
    Am J Surg 185:476-80. 2003
  2. ncbi request reprint The Virginia Mason approach to localized pancreatic cancer
    Vincent J Picozzi
    Section of Hematology Oncology, Virginia Mason Medical Center, 1100 9th Avenue, Seattle, WA 98111, USA
    Surg Oncol Clin N Am 13:663-74, ix. 2004
  3. doi request reprint Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective
    Vincent J Picozzi
    Digestive Disease Institute, Virginia Mason Medical Center, Seattle, WA, USA
    Ann Surg Oncol . 2017
  4. ncbi request reprint Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma
    V J Picozzi
    Section of Hematology Oncology, Virginia Mason Medical Center, Seattle, Washington 98111, USA
    Oncology (Williston Park) 15:1296-306; discussion 1310-1, 1314. 2001
  5. pmc Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031
    V J Picozzi
    Department of Medical Oncology, Virginia Mason Medical Center, Seattle, WA 98111, USA
    Ann Oncol 22:348-54. 2011
  6. ncbi request reprint Strength of the evidence: adjuvant therapy for resected pancreatic cancer
    Vincent J Picozzi
    Section of Medical Oncology, Virginia Mason Medical Center, 1100 Ninth Ave Buck 2, Seattle, WA 98111, USA
    J Gastrointest Surg 12:657-61. 2008
  7. doi request reprint Localized pancreatic cancer with positive peritoneal cytology as a sole manifestation of metastatic disease: a single-institution experience
    Stephen Y Oh
    Digestive Disease Institute, Virginia Mason Medical Center, Seattle, WA, USA
    Am J Surg 213:94-99. 2017
  8. pmc Rare long-term survivors of pancreatic adenocarcinoma without curative resection
    Stephen Y Oh
    Stephen Y Oh, Alicia Edwards, Richard A Kozarek, Digestive Disease Institute, Virginia Mason Medical Center, Seattle, WA 98101, United States
    World J Gastroenterol 21:13574-81. 2015
  9. doi request reprint Afferent limb syndrome and delayed GI problems after pancreaticoduodenectomy for pancreatic cancer: single-center, 14-year experience
    Rahul Pannala
    Department of Gastroenterology and Hepatology, Virginia Mason Medical Center, Seattle, Washington, USA
    Gastrointest Endosc 74:295-302. 2011
  10. doi request reprint Interferon-based Adjuvant Chemoradiation for Resected Pancreatic Head Cancer: Long-term Follow-up of the Virginia Mason Protocol
    Flavio G Rocha
    Section of General, Thoracic, and Vascular Surgery, Virginia Mason Medical Center, Seattle, WA Department of Surgery, Hiroshima University Hospital, Hiroshima, Japan Center for Pancreatic Disease, St Luke s Hospital, Boise, ID Section of Pathology and Laboratory Medicine, Virginia Mason Medical Center, Seattle, WA Section of Gastroenterology, Virginia Mason Medical Center, Seattle, WA Section of Hematology and Oncology, Virginia Mason Medical Center, Seattle, WA
    Ann Surg 263:376-84. 2016

Collaborators

Detail Information

Publications13

  1. ncbi request reprint Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma
    Vincent J Picozzi
    Department of General Surgery, Virginia Mason Medical Center, Seattle, WA 98111, USA
    Am J Surg 185:476-80. 2003
    ..This report describes the continued observations regarding this methodology with longer follow-up and more than twice the number of patients as the original report...
  2. ncbi request reprint The Virginia Mason approach to localized pancreatic cancer
    Vincent J Picozzi
    Section of Hematology Oncology, Virginia Mason Medical Center, 1100 9th Avenue, Seattle, WA 98111, USA
    Surg Oncol Clin N Am 13:663-74, ix. 2004
    ....
  3. doi request reprint Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective
    Vincent J Picozzi
    Digestive Disease Institute, Virginia Mason Medical Center, Seattle, WA, USA
    Ann Surg Oncol . 2017
    ..Successful surgical resection combined with effective perioperative therapy is essential for maximizing long-term survival for pancreatic adenocarcinoma...
  4. ncbi request reprint Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma
    V J Picozzi
    Section of Hematology Oncology, Virginia Mason Medical Center, Seattle, Washington 98111, USA
    Oncology (Williston Park) 15:1296-306; discussion 1310-1, 1314. 2001
    ..02). This assessment of chemotherapy delivery to patients with intermediate-grade NHL showed significant variation from current standards. Further analysis of factors influencing chemotherapy delivery might improve therapeutic outcomes...
  5. pmc Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031
    V J Picozzi
    Department of Medical Oncology, Virginia Mason Medical Center, Seattle, WA 98111, USA
    Ann Oncol 22:348-54. 2011
    ..The American College of Surgeons Oncology Group sought to confirm the efficacy of a novel interferon-based chemoradiation regimen in a multicenter phase II trial...
  6. ncbi request reprint Strength of the evidence: adjuvant therapy for resected pancreatic cancer
    Vincent J Picozzi
    Section of Medical Oncology, Virginia Mason Medical Center, 1100 Ninth Ave Buck 2, Seattle, WA 98111, USA
    J Gastrointest Surg 12:657-61. 2008
    ..Additional randomized trials are needed to address significant areas of controversy within available data...
  7. doi request reprint Localized pancreatic cancer with positive peritoneal cytology as a sole manifestation of metastatic disease: a single-institution experience
    Stephen Y Oh
    Digestive Disease Institute, Virginia Mason Medical Center, Seattle, WA, USA
    Am J Surg 213:94-99. 2017
    ..Pancreatic cancer patients with positive peritoneal cytology (PPC) as a sole metastatic site are poorly characterized. Whether they behave similarly to other stage IV patients is unknown...
  8. pmc Rare long-term survivors of pancreatic adenocarcinoma without curative resection
    Stephen Y Oh
    Stephen Y Oh, Alicia Edwards, Richard A Kozarek, Digestive Disease Institute, Virginia Mason Medical Center, Seattle, WA 98101, United States
    World J Gastroenterol 21:13574-81. 2015
    ..Factors such as tumor biology and host immunity may play a key role in disease progression and survival. ..
  9. doi request reprint Afferent limb syndrome and delayed GI problems after pancreaticoduodenectomy for pancreatic cancer: single-center, 14-year experience
    Rahul Pannala
    Department of Gastroenterology and Hepatology, Virginia Mason Medical Center, Seattle, Washington, USA
    Gastrointest Endosc 74:295-302. 2011
    ..There are limited data on the incidence of afferent limb syndrome and other delayed GI problems in pancreatic cancer (PaC) patients, especially among long-term survivors (>2 years)...
  10. doi request reprint Interferon-based Adjuvant Chemoradiation for Resected Pancreatic Head Cancer: Long-term Follow-up of the Virginia Mason Protocol
    Flavio G Rocha
    Section of General, Thoracic, and Vascular Surgery, Virginia Mason Medical Center, Seattle, WA Department of Surgery, Hiroshima University Hospital, Hiroshima, Japan Center for Pancreatic Disease, St Luke s Hospital, Boise, ID Section of Pathology and Laboratory Medicine, Virginia Mason Medical Center, Seattle, WA Section of Gastroenterology, Virginia Mason Medical Center, Seattle, WA Section of Hematology and Oncology, Virginia Mason Medical Center, Seattle, WA
    Ann Surg 263:376-84. 2016
    ..To report the long-term impact of adjuvant interferon-based chemoradiation therapy (IFN-CRT) after pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma (PDAC)...
  11. doi request reprint Supportive care considerations during concurrent chemoradiotherapy for pancreatic adenocarcinoma: lessons learned from clinical experience
    Andrea Wang-Gillam
    Division of Hematology Oncology, Siteman Cancer Center, Washington University in St Louis School of Medicine, St Louis, MO Department of Radiation Oncology, Rush University Medical Center Department of Surgery, University of Chicago Medical Center, Chicago, IL Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX Cancer and Digestive Diseases Institutes, Virginia Mason Medical Center, Seattle, WA
    Am J Clin Oncol 36:637-43. 2013
    ..Planning for the treatment of side effects before the anticancer therapy begins facilitates therapy administration and improves patient tolerance. ..
  12. ncbi request reprint Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma
    Andrew D Jacobs
    Section of Hematology Oncology, Virginia Mason Medical Center, Seattle, Washington 98111, USA
    Cancer Invest 22:505-14. 2004
    ..To assess the efficacy and toxicity of combination therapy with gemcitabine and docetaxel in patients with unresectable pancreatic carcinoma...
  13. ncbi request reprint Using Experience-Based Design to Improve the Care Experience for Patients With Pancreatic Cancer
    Ann Hagensen
    Virginia Mason Medical Center, Seattle, WA
    J Oncol Pract 12:e1035-e1041. 2016
    ..Despite the importance of the patient care experience to quality and outcome, the literature detailing the care experience in patients with pancreatic cancer is limited...